Theramex to Acquire Commercial Rights of MSD’s Zoely to Expand its Footprints

 Theramex to Acquire Commercial Rights of MSD’s Zoely to Expand its Footprints

Theramex to Acquire Commercial Rights of MSD’s Zoely to Expand its Footprints

Shots:

  • Theramax acquires commercialization rights of Zoely, allowing it to commercialize the therapy in 50+ countries globally. Earlier, Theramax has right to commercialize Zoely in eleven countries in the EU while MSD retains rights in the US and Canada
  • The acquisition of further rights of Zoely expands Theramex global footprints by providing innovative therapies to maintain the healthcare of women
  • Zoely is a combined oral contraceptive therapy consisting of two steroid hormones; 17-beta estradiol and nomegestrol acetate

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Theramex

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post